Measurement of newly developed tumor markers and molecular markers in health screening for lung cancer

新开发的肿瘤标志物和分子标志物在肺癌健康筛查中的测定

• 批准号: 18590849
• 负责人: SHIMIZU Eiji
• 金额: $ 2.04万
• 依托单位: Tottori University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2006
• 资助国家: 日本
• 起止时间: 2006 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18590849/
• 关键词: lung cancer; serum; tumor marker; ProGRP; ULBP-2; anti-p53 autoantibody; コチニン

To establish serum markers for early diagnosis of lung cancer, we developed methods to detect a candidate for molecular marker. In addition, we conducted a large scale survey to confirm the performance of this marker in combination with known tumor markers, to detect lung cancer among healthy people. First, we developed Enzyme-Linked Immunosorbent Assay (ELISA) for detecting soluble ULBP-2. This ELISA system could detect elevated ULBP-2 in serum of lung cancer patients, but not in normal volunteers. These results indicated the usefulness of the ELISA systems. Secondly, to study the performance of the molecular and tumor markers in health screening for lung cancer, we recruited healthy volunteers in group health examination settings. We measured ProGRP, ULBP-2, anti-p53 autoantibody, and cotinine as a marker for small cell lung cancer, non-small cell lung cancer, lung cancer, and smoking habits, respectively. As a result, we revealed that these markers are independent indicators. Thirdly, we developed a new recruitment system to obtain complete personal information of the participants. We got 163 new participants using this system. Serum ProGRP was elevated in two (?20.0 pg/mL), but not exceed a normal level (46.0 pg/mL). Serum ULBP-2 was mildly (2 - 10 ng/ml), moderately (10 - 100 ng/ml), or highly (?100 ng/ml) elevated in five, three, or one subjects, respectively. We are planning to follow up this study population to find the onsets of lung cancer. In summary, supported by this grant, we made a sensitive method to detect a potential candidate of the molecular marker of lung cancer, verified the usefulness of it in combination with kwon tumor maker and autoantibody in cancer screening. In addition, we developed a new system of mass survey to confirm their performance in health screening settings. We believe this will lead to the development of new serum indicators for early detection of lung cancer.

为了建立用于肺癌早期诊断的血清标志物，我们开发了检测候选分子标志物的方法。此外，我们还进行了大规模调查，以确认该标记物与已知肿瘤标记物结合的性能，以检测健康人群中的肺癌。首先，我们开发了用于检测可溶性 ULBP-2 的酶联免疫吸附测定 (ELISA)。该 ELISA 系统可以检测肺癌患者血清中升高的 ULBP-2，但不能检测正常志愿者血清中的 ULBP-2。这些结果表明了 ELISA 系统的有用性。其次，为了研究分子和肿瘤标志物在肺癌健康筛查中的表现，我们在团体健康检查环境中招募了健康志愿者。我们测量了 ProGRP、ULBP-2、抗 p53 自身抗体和可替宁，分别作为小细胞肺癌、非小细胞肺癌、肺癌和吸烟习惯的标志物。结果，我们发现这些标记是独立的指标。第三，我们开发了新的招募系统，以获取参与者的完整个人信息。我们有 163 名新参与者使用该系统。血清 ProGRP 两次升高（≥20.0 pg/mL），但未超过正常水平（46.0 pg/mL）。五名、三名或一名受试者的血清 ULBP-2 分别轻度（2 - 10 ng/ml）、中度（10 - 100 ng/ml）或高度（≥100 ng/ml）升高。我们计划对这个研究人群进行随访，以发现肺癌的发病情况。总之，在这笔资金的支持下，我们建立了一种灵敏的方法来检测肺癌分子标志物的潜在候选者，并验证了其与kwon肿瘤标志物和自身抗体结合在癌症筛查中的有用性。此外，我们开发了一种新的大规模调查系统，以确认他们在健康筛查环境中的表现。我们相信这将导致用于肺癌早期检测的新血清指标的开发。

项目成果

Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele.

肺癌患者接受伊立替康化疗后出现严重毒性：SLCO1B1*15 等位基因纯合子。

• DOI: 10.1097/ftd.0b013e3181357364
• 发表时间: 2007-10-01
• 期刊: Therapeutic drug monitoring
• 影响因子: 2.5
• 作者: H. Takane;M. Miyata;N. Burioka;J. Kurai;Y. Fukuoka;H. Suyama;Y. Shigeoka;K. Otsubo;I. Ieiri;E. Shimizu
• 通讯作者: E. Shimizu

肺癌細胞株におけるセツキシマブを介した抗体体存的細胞傷害活性の検討

肺癌细胞系中西妥昔单抗介导的抗体细胞毒活性的检查

• 发表时间: 2007
• 作者: 倉井 淳; 他
• 通讯作者: 他

Frequent EGFR mutations in brain metastases of lung adenocarcinoma

肺腺癌脑转移中EGFR频繁突变

• DOI: 10.1002/ijc.21940
• 发表时间: 2006-09-15
• 期刊: International Journal of Cancer
• 影响因子: 6.4
• 作者: S. Matsumoto;Kenji Takahashi;Reika Iwakawa;Y. Matsuno;Y. Nakanishi;T. Kohno;E. Shimizu;J. Yokota
• 通讯作者: J. Yokota

Diverse activation states of RhoA in human lung cancer cells:contribution of G protein coupled receptors

人肺癌细胞中RhoA的多种激活状态：G蛋白偶联受体的贡献

• 发表时间: 2007
• 作者: Touge H.; et. al.
• 通讯作者: et. al.

Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells.

地塞米松通过恢复 BT-474 乳腺癌细胞中的 AKT 活性来干扰曲妥珠单抗诱导的细胞生长抑制。

• DOI: 10.3892/ijo.32.3.683
• 发表时间: 2008-03-01
• 期刊: International journal of oncology
• 影响因子: 5.2
• 作者: T. Sumikawa;Y. Shigeoka;T. Igishi;H. Suyama;A. Yamasaki;Kiyoshi Hashimoto;S. Matsumoto;K. Takeda;Y. Ueda;E. Shimizu
• 通讯作者: E. Shimizu